Pic: Talaj (iStock / Getty Images Plus) via Getty Images.
Weed Week: The Super Bowl bans weed ads even though Snoop is the halftime act
News
share
Snoop Dogg is doing the halftime show at the Super Bowl this year, but the NFL won’t be showing any weed ads.
Advertisers can promote liquor and sports betting apps, but cannabis is in the restricted category.
It’s a weird move considering Snoop is a well publicised weed fan, and it would be prime time to target his audience.
But distilled spirits did get off the naughty list in 2017 so there’s still hope the cannabis can make the cut sometime in the future.
What’s the bet that Snoop will just whip out a blunt on stage?
Snoop Dogg smoking and other crazy prop bets for the #SuperBowlhttps://t.co/TXh5LS929j
— Offside (@OffsideDH) February 5, 2022
On our side of the pond, Curtin University has teamed up with Little Green Pharma (ASX:LGP) to explore the use of medicinal cannabis treatment options for obesity and related health issues.
It’s basically the opposite of the munchies. The aim of the research is to identify one or more combinations of cannabinoids that may produce effects in the gastrointestinal tract to induce a feeling of fullness and a decrease in appetite, potentially leading to weight loss and even diabetes reversion.
Curtin Medical School’s Professor Falasca said the research could be a game-changer for those struggling with obesity and type 2 diabetes.
“Some of the more than 100 cannabinoids present in the cannabis plant cannabinoids have been shown to have therapeutic potential for obesity,” he said.
“Our research will seek to unlock further understanding of the role these cannabinoids can play in regulating gut function, their mechanism of action and optimal dosing for therapeutic effect to help weight loss.”
If all goes to plan, the next stage is testing the drugs in human trials.
ASX WEED STOCKS
| Code | Company | Price | % Six Month | % Month | % Week | Market Cap |
|---|---|---|---|---|---|---|
| CAU | Cronos Australia | 0.35 | 204% | 19% | 21% | $181,706,388.27 |
| TSN | The Sust Nutri Grp | 0.19 | -44% | 12% | 19% | $19,297,021.60 |
| AC8 | Auscann Grp Hlgs Ltd | 0.083 | -14% | 0% | 15% | $37,887,051.46 |
| ROO | Roots Sustainable | 0.0065 | -41% | 8% | 8% | $4,872,612.47 |
| MDC | Medlab Clinical Ltd | 0.135 | -21% | -7% | 8% | $45,338,276.41 |
| BOD | BOD Australia | 0.215 | -35% | -2% | 8% | $23,281,262.40 |
| BOT | Botanix Pharma Ltd | 0.064 | -18% | 10% | 5% | $60,334,808.59 |
| IRX | Inhalerx Limited | 0.088 | -10% | -12% | 5% | $13,477,356.56 |
| LV1 | Live Verdure Ltd | 0.395 | 46% | -1% | 4% | $16,610,470.88 |
| CPH | Creso Pharma Ltd | 0.088 | -30% | 6% | 4% | $106,856,970.05 |
| EOF | Ecofibre Limited | 0.44 | -43% | -21% | 2% | $167,510,667.84 |
| LGP | Little Green Pharma | 0.56 | -27% | -10% | 2% | $105,662,377.54 |
| ZLD | Zelira Therapeutics | 0.028 | -35% | -10% | 0% | $49,622,177.34 |
| WFL | Wellfully Limited | 0.067 | 3% | -8% | 0% | $16,237,221.98 |
| HGV | Hygrovest Limited | 0.047 | -40% | -15% | 0% | $11,037,791.28 |
| YPB | YPB Group Ltd | 0.002 | 0% | -33% | 0% | $12,235,667.40 |
| SCU | Stemcell United Ltd | 0.014 | -13% | 0% | 0% | $14,606,489.21 |
| MRG | Murray River Grp | 0.245 | 29% | 0% | 0% | $10,808,210.04 |
| NTI | Neurotech Intl | 0.05 | -2% | -12% | 0% | $33,489,558.05 |
| AVE | Avecho Biotech Ltd | 0.016 | -11% | 7% | 0% | $27,567,187.89 |
| PAL | Palla Pharma Ltd | 0.295 | -16% | 0% | 0% | $47,764,383.09 |
| EVE | EVE Health Group Ltd | 0.004 | -20% | -20% | 0% | $15,372,567.56 |
| EPN | Epsilon Healthcare | 0.068 | -55% | 6% | -1% | $14,698,658.63 |
| AGH | Althea Group | 0.21 | -26% | -7% | -2% | $66,101,187.39 |
| EMD | Emyria Limited | 0.355 | 92% | -7% | -3% | $61,216,746.85 |
| ECS | ECS Botanics Holding | 0.03 | -21% | 3% | -3% | $34,308,650.68 |
| CAN | Cann Group Ltd | 0.275 | -13% | -7% | -4% | $94,263,351.75 |
| IHL | Incannex Healthcare | 0.445 | 68% | -34% | -4% | $525,709,681.31 |
| DTZ | Dotz Nano Ltd | 0.38 | 6% | -12% | -5% | $166,928,187.52 |
| RGI | Roto-Gro Intl Ltd | 0.017 | -56% | -23% | -6% | $6,166,670.35 |
| RNO | Rhinomed Ltd | 0.25 | 25% | -15% | -6% | $66,251,328.66 |
| WOA | Wide Open Agricultur | 0.62 | -18% | -11% | -6% | $79,478,899.26 |
| ALA | Arovella Therapeutic | 0.042 | -19% | 11% | -7% | $25,849,497.30 |
| EXL | Elixinol Wellness | 0.066 | -43% | -10% | -8% | $20,850,137.62 |
| MXC | Mgc Pharmaceuticals | 0.03 | -27% | -39% | -9% | $83,715,782.88 |
| CGBDA | Cann Global Limited | 0.041 | -67% | -18% | -11% | $10,390,198.31 |
| IDT | IDT Australia Ltd | 0.225 | -41% | -10% | -15% | $56,263,739.25 |
| EN1 | Engage:Bdr Limited | 0.0015 | -63% | -25% | -25% | $7,005,271.90 |
There were 12 companies in the green this fortnight, with 10 companies flatlining and 16 in the losers column.
Here are the ones with notable news:
AusCann (ASX:AC8)
The company received its official Memorandum of Conference (MOC) from the U.S Food and Drug Administration, Centre for Veterinary Centre (FDA-CVM) – which basically provides clarity on the regulatory pathway for the approval of CPAT-01 as a veterinary medicine in the United States.
It’s a key milestone for the CPAT-01 cannabinoid-based treatment for the control of pain and inflammation in dogs with osteoarthritis.
Especially considering that the global veterinary pain management market is worth over US$1 billion and is projected to grow at a Compound Annual Growth Rate of 8% to reach US$1.6 billion by 2023.
Medlab Clinical (ASX:MDC)
Medlab has nabbed “Favourable Opinion” status from the UK Research Ethics Committee for the upcoming NanaBis Phase 3 trial.
“We can now move forward with final UK clinical trials approval, at which point we will announce the UK Hospitals and Principal Investigators,” CEO and MD Dr Sean Hall said.
NanaBis is a globally patented non-opioid analgesic designed to treat cancer and non-cancer bone pain, and the company plans to start Phase 3 trials with approximately 120 patients in Australia, 120 in the UK and 120 in the USA.
The next step is for Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency.
Creso Pharma (ASX:CPH)
The company is gearing up to enter the US CBD market by acquiring established female founded business Sierra Sage Herbs LLC and the leading Green Goo brand.
It will provide Creso with revenue generating operations, with Sierra Sage Herbs generating US$5.7m in revenue in CY2021, and poised to grow.
The Green Goo and Southern Butter product ranges are currently sold across 90,000 distribution points in the US, with an additional 20,000 sales points expected to be added during Q1 CY2022.
Plus, Sierra Sage Herbs has an established ecommerce operation, with a growing customer base of over 150,000 consumers across the country.
And Creso says the US CBD market is flagged to grow in value to US$12b by 2026.
“It marks entry into the US CBD market and provides a strong foundation to rapidly scale up operations, product development and sales, as well as further M&A transactions,” CEO and MD William Lay says.
“We intend to aggressively leverage these relationships and the group’s existing customer base by introducing them to Creso Pharma’s existing product suite for human health, animal health and sports and recovery.”
The company plans to hold a shareholders’ meeting to approve the transaction in or around late March 2022.
